Navigation Links
MPs in Biological Technology

Mach One Subsidiary Modular Process Constructors LLC Changes Name to MPS BioPharm to Better Reflect its Vision

Announces significant contract with Major Biopharmaceutical Company BELGIUM, Wis., March 6 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), is pleased to announce that its subsidiary, Modular Process Constructors LLC, is changing its name to MPS BioPharm to better reflect i...

BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome

NOVATO, Calif., June 5 /PRNewswire-FirstCall/ - BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced its program for its third enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis IVA (MPS IVA), or Morquio A Syndrome. BioMarin plans to initiate a Phase 1/2...

Kuvan Receives Priority Review Status From Health Canada

...ment for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Jefferies Healthcare Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Goldman Sachs Healthcare Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Deutsche Bank Health Care Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Baird Growth Stock Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin Announces First Quarter 2009 Financial Results

...g programs including PEG-PAL for PKU and GALNS for mps IVA. We are strategically developing earlier stag...ial are expected in mid-2010. GALNS for mps IVA: BioMarin initiated the Phase I/II trial in m... 1H10: Results from Phase I/II trial for GALNS for mps IVA Mid-2010: Results from PEG-PAL Phase I...

Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors

...ilize MPS' Equity by Design (TM) product. mps will evaluate all equipment designs for fit and pu...lated to design, constructability and cleanliness. mps will also provide a final report, identifying budg...id, "Equity by Design(TM) is a program whereby mps provides certain Technical Advisory Services in wh...

BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA

...me replacement therapies, one for the treatment of mps I and one for the treatment of mps VI. Naglazyme(R) (galsulfase) for mps VI is wholly developed and commercialized by BioMa...

BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results

...the advancement of several programs including PEG-PAL for PKU and GALNS for mps IVA. We also plan to continue making investments in growth opportunities a...se 2 PAH trial -- 1Q09/2Q09: Initiation of Phase 1 trial for GALNS for mps IVA -- 2Q09: Results from proteinuria in chronic kidney disease trial ...

Naglazyme Approved by Brazil's National Health Surveillance Agency

...zil which has the largest known number of affected mps VI patients in the world," said Stephen Aselage, S...) in January 2006. As the first drug approved for mps VI, the FDA and EC have both designated Naglazyme ...t exclusivity in the European Union. About mps VI ...

Mach One Corporation Enters Letter of Intent

...saction with Modular Process Constructors LLC (dba mps BioPharm) (the "Seller" or "BioPharm") to acquire ... About Modular Process Constructors LLC (dba mps BioPharm) mps BioPharm currently designs and builds skid based s...

Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics

... (galsulfase) and enzyme replacement therapies for mps IVA (Morquio Syndrome) and Pompe disease will be p...for symptomatic spinal cord compression (SCC) in a mps VI child: safety, efficacy, and pitfalls" 763/W ...ears of Galsulfase ERT in five adult patients with mps VI" 2353/W - "MPS Brazil-Network: 4 years improv...

BioMarin Announces Third Quarter 2008 Financial Results

...xpansion of Naglazyme, and the timely development of the PEG-PAL, GALNS for mps IVA and other promising pipeline programs." Net Product Revenue Net pro...ic kidney disease trial -- 1Q09: Initiation of Phase 1 trial for GALNS for mps IVA -- 1Q09/2Q09: Results from PEG-PAL Phase 1 trial -- 1Q09/2Q09: Initia...

Naglazyme Approved by Japanese Ministry of Health

...Ges in bringing the first drug treatment option to mps VI patients in Japan," said Stephen Aselage, Senio...C) in January 2006. As the first drug approved for mps VI, the FDA and EC have both designated Naglazyme ...ation in June 2007 from the MHLW in Japan. About mps VI ...

BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture

...rojects which could lead to important advances for mps I patients." About mps I mps I is a rare, progressive, heterogeneous, debilitat...

Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics

...e (galsulfase) Enzyme Replacement Therapy (ERT) in mps VI (Maroteaux-Lamy Syndrome) patients Presented b...sserstein) -- 1495 -- Clinical Characteristics of mps I patients in the mps I Registry (Bodamer) -- 2241 -- Urinary GAG ...

Genzyme Receives Approval to Market Elaprase(R) in Japan

... Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme(R) (agalsidase beta) for Fabry disease; Aldurazyme(R) (laronidase) for mps I; and Myozyme(R) (alglucosidase alfa) for Pompe disease. "Our deep experience in Japan in the area of lysosomal storage disorders will enable us to ...

Genzyme Begins Major Expansion of Boston Manufacturing Facility

... alfa) for Pompe disease. Genzyme also performs the filling and packaging for two products manufactured at other sites: Aldurazyme(R) (laronidase) for mps I disease and Thyrogen(R) (thyrotropin alfa for injection), used in the screening of patients who have had thyroid cancer. Genzyme last expanded the s...

Educate, innovate and execute: Wisconsins model for success

...m rather than how much is spent administratively. mps simply spends too much money on employee costs (i....nefits, pension) than is manageable. In fact, the mps Board boosted the tax levy for 2003-'04 by more th...$11 million, or a 5.8 percent increase. This year, mps is projecting a 15% increase as a stopgap to keep ...
Other Tags
(Date:8/1/2014)... The Journal of Nutrition Education and Behavior (JNEB) announces ... (GEM) awards, which were presented at the Society for ... Impact: Local to Global," in Milwaukee, Wisconsin, June 28 ... the authors of the best article and best GEM ... of the JNEB Journal Committee and Board of Editors. ...
(Date:8/1/2014)... of a new study, including two Simon Fraser ... industry representatives and policymakers must collaborate closely on ... gas development. Viorel Popescu and Maureen Ryan, David ... Sciences department, are among eight international co-authors of ... Ecology and the Environment . , Shale gas ...
(Date:7/31/2014)... tracing nearly 3,000 genes to the earliest common ... scientists have created an extensive "Tree of Lepidoptera" ... DNA sequencing. , Among the study,s more ... small moths than to large ones, which completely ... study also found that some insects once classified ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3
(Date:8/1/2014)... The European gas chromatography systems report defines and segments the ... The gas chromatography systems market in Europe is valued at ... around $247.6 million by 2018, at a CAGR of 5.3% ... the European gas chromatography systems market, to get an idea ... of the segmentation of gas chromatography systems market in the ...
(Date:8/1/2014)... 2014 The North America Sports Drink Market ... America, with analysis and forecast of revenue. The Sports Drink ... $5,021.9 million in 2012 to $6,243 million by 2018, at ... through the TOC of the North America Sports Drink market ... This also provides a glimpse of the segmentation in the ...
(Date:8/1/2014)... Gerontological Society of America (GSA) the ... aging has chosen Carole B. Lewis, PT, DPT, ... recipient of the Excellence in Rehabilitation of Aging Persons ... acknowledge outstanding contributions in the field of rehabilitation. The ... or patient care, or publications that may include scholarly ...
(Date:8/1/2014)... Home Care Assistance of Cincinnati , ... to be recognized as a 2014 Best of Home Care ... care providers who rank in the top 50th percentile in ... interviews conducted by Home Care Pulse. , “The Best ... the best of the best!” says Home Care Pulse Founder ...
(Date:8/1/2014)... 01, 2014 With fast food restaurants on ... convenience of processed, microwavable dinners, it is no wonder that ... offer patients a mere quick fix for shedding this dangerous ... part of the country, get slimmer and healthier for the ... the tools and education on how to avoid obesity ...
Breaking Medicine News(10 mins):Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 3
Other Contents